Wu Xiaobin sold $400K of ONC

Wu Xiaobin (President and COO) sold 1,484 shares of BeOne Medicines Ltd. (ONC) at an average of $269.37 ($269.33–$270.55, $0.40M total) across 2 trades on 2026-06-08.

Original reporting
SEC EDGAR · Wu Xiaobin
Published Jun 10, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

Traders may monitor for clustering of insider sales or follow-on disclosures, but this single transaction is unlikely to reset valuation without accompanying operational/regulatory catalysts.

02

Market read

A modest insider sale was newly disclosed; it may cause brief sentiment noise but lacks fundamental substance in the text.

03

What to watch

The filing shows the executive ended with 0 shares, but the article provides no context on compensation, option exercises, or prior holdings beyond the post-transaction balance.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-10; sale executed 2026-06-08

Background

The article is a primary SEC Form 4 disclosure reporting an officer’s open-market sale of ONC shares.

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines (ONC) disclosed an insider open-market sale by President/COO Wu Xiaobin of 1,484 shares (~$399.7K) on 2026-06-08 via Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional insider selling or fundamental news.

Evidence & confidence

Form 4 insider sales are primary-source but typically have low predictive power; the transaction is moderate (~$0.4M) and lacks a stated 10b5-1 plan, which can add marginal interpretive risk.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales often reflect diversification, taxes, or pre-planned liquidity needs; absence of a stated 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • BeOne Medicines Ltd.

    Company whose shares were sold by an insider (Form 4).

  • Wu Xiaobin

    President and COO who sold 1,484 ONC shares on 2026-06-08.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ONCMed

BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion

BeOne Medicines reported Q3 2026 earnings, highlighting Brukinsa's U.S. sales exceeding $1 billion. Management discussed competitive threats, R&D investments, and clinical trial updates. Operating margins are expected to expand by over 10% in 2026, with future growth balanced against investment. The company is expanding its CDK4 inhibitor Phase III study and partnering with Revolution Medicines on precision oncology initiatives.

$ONCHighAI 8/10

Jefferies raises BeOne Medicines stock price target on solid quarter

Jefferies raised its price target for BeOne Medicines (ONC) to $470 from $410, citing strong quarterly results and raised guidance. The stock trades near its 52-week high at $387.27. The company reported $1.7B in Q2 2026 revenue, up 29% YoY, and raised its full-year 2026 revenue guidance to $6.6B-$6.8B. Analysts highlight robust margins, revenue growth, and a solid pipeline.

$ONCHighAI 9/10

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,

$ONCMed

BeOne Medicines Receives FDA Priority Review for BRUKINSA Combination in First-Line Mantle Cell Lymphoma

BeOne Medicines (ONC) announced FDA Priority Review for BRUKINSA (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, based on Phase 3 MANGROVE trial results showing 43% reduced risk of disease progression or death. If approved, it would be the first chemotherapy-free regimen for this indication. The company is also seeking approvals in Europe and China. BRUKINSA is already approved for other B-cell malignancies.